Kneteman, Norman M.

Publishing since 1987 (Dinosaur)

Has published 133 publications in 24 years

Number of publications published per year by Kneteman, Norman M.. (Source : PubMed)

Distribution of publications types for Kneteman, Norman M.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Kawahara T, Douglas DN, Lewis J, Lund G, Addison W, Tyrrell DL, Churchill TA, Kneteman NM. Critical role of natural killer cells in the rejection of human hepatocytes after xenotransplantation into immunodeficient mice.  Transpl. Int.  2010  
•  Douglas DN, Kawahara T, Sis B, Bond D, Fischer KP, Tyrrell DL, Lewis JT, Kneteman NM. Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.  PLoS ONE  2010;5;2  
•  Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.  Hepatology  2009  
•  Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria.  Transpl. Int.  2009;22;9  
•  VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, Dowler MG, Sacci JB, Kangwanrangsan N, Tsuboi T, Kneteman NM, Heppner DG, Murdock BA, Mikolajczak SA, Aly AS, Cowman AF, Kappe SH. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design.  Proc. Natl. Acad. Sci. U.S.A.  2009;106;31  
•  Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.  Hepatology  2009;49;3  
•  Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DL, Immermann F, Chaudhary I, Speth J, Villano SA, O'Connell J, Collett M. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.  Hepatology  2009;49;3  
•  Laporte MG, Jackson RW, Draper TL, Gaboury JA, Galie K, Herbertz T, Hussey AR, Rippin SR, Benetatos CA, Chunduru SK, Christensen JS, Coburn GA, Rizzo CJ, Rhodes G, O'Connell J, Howe AY, Mansour TS, Collett MS, Pevear DC, Young DC, Gao T, Tyrrell DL, Kneteman NM, Burns CJ, Condon SM. The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.  ChemMedChem  2008;3;10  
•  Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma.  Liver Transpl.  2008;14;8  
•  Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.  Nat. Med.  2008;14;1  

[ See timeline ] [ See all publications ]